Trial Profile
A Phase II, Multi-center, Randomized, Parallel Group, Double-blind, MTX Controlled Study to Assess the Clinical Efficacy, Safety and Tolerability of CH-4051 in Patients With Active RA Who Have Shown an Inadequate Response to MTX Monotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs CH 4051 (Primary) ; Folic acid; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms MOTION
- 02 Jun 2012 Additional locations (Argentina, Mexico, Poland) added and company (Hospira) added as reported by European Clinical Trials Database record.
- 31 May 2012 Primary endpoints 'American-College-of-Rheumatology-response-criteria' (hybrid score) and 'American-College-of-Rheumatology-20%-response-criteria' have not been met according to a Chelsea Therapeutics media release.
- 31 May 2012 Results have been reported in a Chelsea Therapeutics media release.